Ticker

Analyst Price Targets — NAGE

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
May 11, 2026 10:03 amH.C. Wainwright$11.00$4.17TheFly Niagen Bioscience price target lowered to $11 from $12 at H.C. Wainwright
May 5, 2026 10:48 amCanaccord Genuity$10.00$4.93TheFly Niagen Bioscience price target lowered to $10 from $13 at Canaccord
November 5, 2025 2:21 pmCanaccord Genuity$14.00$7.03TheFly Niagen Bioscience price target lowered to $14 from $16 at Canaccord

Latest News for NAGE

Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the appointment of Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026.Dr. Kale will lead Niagen Bioscience's Global Niagen Research Program, overseeing the…

Business Wire • Jul 16, 2026
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia…

Business Wire • Jul 13, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for NAGE.

No House trades found for NAGE.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top